| 000 | 01634 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250516204201.0 | ||
| 264 | 0 | _c20140618 | |
| 008 | 201406s 0 0 jpn d | ||
| 022 | _a0485-1439 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aOhmachi, Ken | |
| 245 | 0 | 0 |
_a[Recommendation for the optimal use of bendamustine in Japan]. _h[electronic resource] |
| 260 |
_b[Rinsho ketsueki] The Japanese journal of clinical hematology _c03 2014 |
||
| 300 |
_a311-20 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Murine-Derived _xadministration & dosage |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 | _aBendamustine Hydrochloride |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 |
_aCytomegalovirus Infections _xcomplications |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 |
_aDrug Eruptions _xetiology |
| 650 | 0 | 4 | _aEvidence-Based Medicine |
| 650 | 0 | 4 |
_aHepatitis B _xcomplications |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunocompromised Host |
| 650 | 0 | 4 | _aJapan |
| 650 | 0 | 4 |
_aLymphoma, B-Cell _xblood |
| 650 | 0 | 4 |
_aLymphoma, Mantle-Cell _xblood |
| 650 | 0 | 4 |
_aNausea _xchemically induced |
| 650 | 0 | 4 |
_aNitrogen Mustard Compounds _xadministration & dosage |
| 650 | 0 | 4 |
_aOpportunistic Infections _xcomplications |
| 650 | 0 | 4 | _aRituximab |
| 650 | 0 | 4 |
_aVasculitis _xetiology |
| 700 | 1 | _aMaruyama, Dai | |
| 700 | 1 | _aNisikori, Momoko | |
| 700 | 1 | _aSuzuki, Tatsuya | |
| 700 | 1 | _aIzutsu, Koji | |
| 773 | 0 |
_t[Rinsho ketsueki] The Japanese journal of clinical hematology _gvol. 55 _gno. 3 _gp. 311-20 |
|
| 999 |
_c23689048 _d23689048 |
||